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We read with great interest the article “Recent advances in the management of chronic 
stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor 
  reduction, and revascularization” by Dr Richard Kones.1
Dr Kones presents an excellent review in which he describes some invasive 
  anti-anginal therapies for the treatment of those ill-fated patients who suffer from 
refractory angina pectoris (RAP), a type of angina pectoris that persists despite optimal 
medical therapy, in patients who are not candidates for revascularization.
Dr Kones discusses five invasive antianginal therapies for refractory angina: 
spinal cord stimulation, enhanced external counterpulsation, transmyocardial laser 
  revascularization, stem cell/gene therapy, and percutaneous coronary intervention 
(PCI), all of which are options for a selected group of patients only. However, one 
emerging innovation for the treatment of patients suffering from RAP has been 
  overlooked, namely that of coronary sinus intervention.
We would like to add a comment to Dr Kones’ excellent review and present some 
historical facts and medical information about the Neovasc coronary sinus reducer stent 
(CSRS) for the treatment of patients with RAP who are not candidates for coronary 
artery revascularization, either coronary artery bypass grafting or PCI. In the mid 1990s 
we initiated an unusual, novel approach to support the ischemic myocardium, which we 
called “the upside-down strategy”. This means we initially catheterized the coronary 
venous system instead of the coronary arteries, arriving at the coronary sinus, and 
  secondly reduced the coronary sinus effective cross area instead of expanding a narrowed 
coronary artery. We were very surprised with the results of our initial   studies in pig 
models, since we noticed that permanent constriction of the coronary sinus caused some 
kind of epicardial and intramyocardial neovascularization/  angiogenesis of medium-
size blood vessels, compared with untreated pigs. These new or   dormant blood vessels 
could be seen even at the macroscopic level. Following several   developmental stages, 
we produced the first percutaneous intravenous CSRS, which we called “  Neovasc”, and 
which later became known as Neovasc Medical, Inc (Richmond, Canada).
The CSRS is a balloon-expandable stent, implanted by a percutaneous transvenous 
approach through the right internal jugular vein or any other large peripheral vein. It has 
a unique shape that reduces the coronary sinus diameter to 3 mm, thereby reducing, 
rather than increasing, coronary circulation output.
The first human study, a prospective, open-labeled, safety feasibility study, began 
in 2004.2 The CSRS was implanted in 15 patients with angina pectoris refractory Vascular Health and Risk Management
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to medical   treatment. All patients underwent uneventful 
implantations without procedure-related complications, and 
were   discharged from hospital 1 to 2 days later. No major 
adverse cardiac events were reported during a follow-up 
period of 6 months, at which time most of the patients had 
improved Canadian Cardiovascular Society (CCS) scores 
compared with baseline (3.07 versus 1.64; P , 0.0001). 
Improvement was also seen for stress-induced ST-segment 
depression, as well as for the extent and severity of myocar-
dial   ischemia, as shown either by dobutamine echocardiog-
raphy or by   thallium single-photon emission CT.
Three years follow-up of the patients has now been 
completed without mortality, myocardial infarctions, or 
device-related adverse events, while clinical   improvements 
remain constant, as measured by CCS at 6 months of 
follow-up.3 Eleven patients underwent CT angiography 
after 3 years and all CSRSs were patent and well located in 
the coronary sinus. These findings suggest that the   Neovasc 
reducer stent may be a safe, feasible, comfortable, and 
effective option for many patients suffering from coronary 
artery disease.
The Coronary Sinus Reducer for Treatment of   Refractory 
Angina (COSIRA) study is a recent clinical multicenter 
trial that will reassess the efficacy of the CSRS.4 Patient 
enrollment began in September 2010. On September 27, 
2010, the   Neovasc CSRS was featured in a “live case” 
performed in the Antwerp Cardiovascular Institute/ZNA 
Middelheim in Belgium and broadcast to the main arena 
of the Transcatheter   Cardiovascular Therapeutics 2010, 
the 22nd Annual Scientific Symposium sponsored by the 
Cardiovascular Research Foundation.5 The Neovasc CSRS 
was successfully implanted by the COSIRA trial principal 
investigator into the coronary sinus of a patient suffering 
from refractory angina pectoris.
We hope that by improving quality of life and survival, 
implantation of the Neovasc CSRS will prove to be the optimal 
treatment for those patients who suffer from chronic RAP.
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